National Institute of Allergy and Infectious Diseases

[{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Chimeron Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV2 antigen","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"3","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-873","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"PDS Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"PDS0202","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"7 Hills Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"7HP349","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Helocyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"2-deoxy-D-glucose Prodrug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Maxwell Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Antimicrobial Peptides","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Omniose","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Bioconjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"HEPLISAV-B","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Efineptakin Alfa","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"TeraImmune","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"H1ssF-3928 mRNA-LNP","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Not Applicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Universal Influenza Virus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Pluri","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"PLX-R18","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Exavir Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"XVIR-110","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Imunon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"DNA-based Lassa Virus Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ResVita Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RVB-101","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Omniose","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"GBS Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"2","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"ALG-097558","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Ocugen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"OCU500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ReAlta Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"RLS-0071","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"KBio","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"EV68-228-N","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Pluri","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ National Institute of Allergy and Infectious Diseases"}]